AKER Stock News 3.73 05/09/2014 19:38:38 Akers Biosciences (
Post# of 273322
Posted On: 05/09/2014 8:38:39 PM
Akers Biosciences (AKER) 3.73 $AKER
RedChip TV Announces Lineup for This Week's Show on Fox Business and Bloomberg
GlobeNewswire - Thu May 08, 9:20AM CDT
RedChip Companies, Inc. ("RedChip"
, an international small-cap research, investor relations, and media company, today announced that "The RedChip Money Report: Small Stocks Big Money" television program will feature two emerging growth companies on Fox Business nationwide on Thursday, May 8, 2014 at 10:00 p.m. Pacific (1 a.m. EDT). The show will also air on Bloomberg U.K. Saturday, May 10, 2014 at 12:30 a.m. GMT; on Bloomberg Europe on Sunday, May 11, 2014 at 8:30 a.m. and 3:30 p.m. GMT; and on Bloomberg Asia on Sunday May 11, 2014 at 3:30 p.m. HKT.
Akers Biosciences Signs Distribution Agreement for Infectious Disease and Cholesterol Rapid Tests in Middle East, Australia, & Singapore
GlobeNewswire - Wed May 07, 4:06AM CDT
Akers Biosciences, Inc. (Nasdaq:AKER) (LSE:AKR) (the "Company" or "ABI", a leading designer and manufacturer of rapid diagnostic screening and testing products, announces a distribution agreement with Thirty Six Strategies General Trading LLC ("36S", for the sale of the Company's PIFA PLUSS Infectious Disease Rapid Assay product line and Tri-Cholesterol "Check".
Akers Biosciences Starts Clinical Trials for PIFA PLUSS Chlamydia Assay
GlobeNewswire - Wed Apr 30, 1:00AM CDT
Akers Biosciences, Inc. (Nasdaq:AKER) (LSE:AKR) (the "Company" or "ABI", a leading designer and manufacturer of rapid diagnostic screening and testing products, has commenced clinical trials in the USA for its PIFA PLUSS Chlamydia Assay, the world's first rapid test for Chlamydia diagnosis using a finger stick blood sample.
Lucosky Brookman LLP takes Akers Biosciences, Inc. Public on NASDAQ
PR Newswire - Thu Apr 03, 9:00AM CDT
Lucosky Brookman LLP (the "Firm" or "Lucosky Brookman" (www.lucbro.com), a leading corporate finance and securities law firm, has announced that its client Akers Biosciences, Inc. (the "Company" or "Akers Biosciences" (NASDAQ:AKER) has successfully completed an initial public offering of its common stock and commenced trading on the NASDAQ Capital Markets. Lucosky Brookman will join Akers Biosciences to ring the closing bell on the floor of the NASDAQ on July 9, 2014.
Akers Biosciences Announces Its Financial Results for Fiscal 2013
GlobeNewswire - Fri Mar 28, 6:00AM CDT
Akers Biosciences, Inc. (AKR.L) (Nasdaq:AKER), (the "Company" or "Akers", a leading designer and manufacturer of rapid diagnostic screening and testing products, reports its financial results for the fiscal year ended December 31, 2013.
Leading Medical Sales and Marketing Executive to Spearhead Akers Biosciences' Commercialization Strategy
GlobeNewswire - Thu Mar 27, 6:00AM CDT
Akers Biosciences, Inc. (LSE:AKR) (Nasdaq:AKER), (the "Company" or "ABI", a leading designer and manufacturer of rapid diagnostic screening and testing products, announces the appointment of Edwin C. Hendrick as Executive Vice President, Sales and Marketing.
Akers Biosciences Co-Founder and Executive Chairman to Assume Duties of President & CEO
GlobeNewswire - Wed Mar 12, 12:15PM CDT
Akers Biosciences, Inc. (LSE:AKR) (Nasdaq:AKER), (the "Company" or "ABI", a leading designer and manufacturer of rapid diagnostic screening and testing products, today announces that President and CEO Thomas A. Nicolette will be stepping down from the board and leaving the Company, effective March 28, 2014. Mr. Nicolette is the principal of Nicolette Consulting Group Limited, a business management consulting firm specializing in capital raising and financial planning. Through a series of consulting agreements, Mr. Nicolette has held the position of ABI's President since February 2007 and Chief Executive Officer since April 2008. Most recently, he played an integral role in ABI's successful listing on the NASDAQ Capital Market raising $15 million to support ABI's growth. Raymond F. Akers, Jr. PhD, the Company's Co-founder and Executive Chairman of the Board will assume the duties of President and CEO effective March 28, 2014; Mr. Nicolette will assist in the transition.
Akers Biosciences, Inc. Announces Pricing of Public Offering of Common Stock and Listing on NASDAQ
GlobeNewswire - Thu Jan 23, 12:05PM CST
Akers Biosciences, Inc. (LSE:AKR) (Nasdaq:AKER), (the "Company" or "Akers Biosciences), a leading designer and manufacturer of rapid diagnostic screening and testing products, today announced the pricing of an underwritten public offering of 2,727,000 shares (the "Shares" of common stock at a public offering price of $5.50 per share. The shares will begin trading on The NASDAQ Capital Market on January 23, 2014 at approximately 2:10 PM EST under the symbol "AKER." The Company expects to receive approximately $15,000,000 in gross proceeds, before underwriting discounts and commissions and offering expenses payable by the Company. The Company has granted the representative of the underwriters a 45-day option to purchase up to 409,050 additional shares of common stock.
RedChip TV Announces Lineup for This Week's Show on Fox Business and Bloomberg
GlobeNewswire - Thu May 08, 9:20AM CDT
RedChip Companies, Inc. ("RedChip"
, an international small-cap research, investor relations, and media company, today announced that "The RedChip Money Report: Small Stocks Big Money" television program will feature two emerging growth companies on Fox Business nationwide on Thursday, May 8, 2014 at 10:00 p.m. Pacific (1 a.m. EDT). The show will also air on Bloomberg U.K. Saturday, May 10, 2014 at 12:30 a.m. GMT; on Bloomberg Europe on Sunday, May 11, 2014 at 8:30 a.m. and 3:30 p.m. GMT; and on Bloomberg Asia on Sunday May 11, 2014 at 3:30 p.m. HKT. Akers Biosciences Signs Distribution Agreement for Infectious Disease and Cholesterol Rapid Tests in Middle East, Australia, & Singapore
GlobeNewswire - Wed May 07, 4:06AM CDT
Akers Biosciences, Inc. (Nasdaq:AKER) (LSE:AKR) (the "Company" or "ABI"
, a leading designer and manufacturer of rapid diagnostic screening and testing products, announces a distribution agreement with Thirty Six Strategies General Trading LLC ("36S", for the sale of the Company's PIFA PLUSS Infectious Disease Rapid Assay product line and Tri-Cholesterol "Check". Akers Biosciences Starts Clinical Trials for PIFA PLUSS Chlamydia Assay
GlobeNewswire - Wed Apr 30, 1:00AM CDT
Akers Biosciences, Inc. (Nasdaq:AKER) (LSE:AKR) (the "Company" or "ABI"
, a leading designer and manufacturer of rapid diagnostic screening and testing products, has commenced clinical trials in the USA for its PIFA PLUSS Chlamydia Assay, the world's first rapid test for Chlamydia diagnosis using a finger stick blood sample. Lucosky Brookman LLP takes Akers Biosciences, Inc. Public on NASDAQ
PR Newswire - Thu Apr 03, 9:00AM CDT
Lucosky Brookman LLP (the "Firm" or "Lucosky Brookman"
(www.lucbro.com), a leading corporate finance and securities law firm, has announced that its client Akers Biosciences, Inc. (the "Company" or "Akers Biosciences" (NASDAQ:AKER) has successfully completed an initial public offering of its common stock and commenced trading on the NASDAQ Capital Markets. Lucosky Brookman will join Akers Biosciences to ring the closing bell on the floor of the NASDAQ on July 9, 2014. Akers Biosciences Announces Its Financial Results for Fiscal 2013
GlobeNewswire - Fri Mar 28, 6:00AM CDT
Akers Biosciences, Inc. (AKR.L) (Nasdaq:AKER), (the "Company" or "Akers"
, a leading designer and manufacturer of rapid diagnostic screening and testing products, reports its financial results for the fiscal year ended December 31, 2013. Leading Medical Sales and Marketing Executive to Spearhead Akers Biosciences' Commercialization Strategy
GlobeNewswire - Thu Mar 27, 6:00AM CDT
Akers Biosciences, Inc. (LSE:AKR) (Nasdaq:AKER), (the "Company" or "ABI"
, a leading designer and manufacturer of rapid diagnostic screening and testing products, announces the appointment of Edwin C. Hendrick as Executive Vice President, Sales and Marketing. Akers Biosciences Co-Founder and Executive Chairman to Assume Duties of President & CEO
GlobeNewswire - Wed Mar 12, 12:15PM CDT
Akers Biosciences, Inc. (LSE:AKR) (Nasdaq:AKER), (the "Company" or "ABI"
, a leading designer and manufacturer of rapid diagnostic screening and testing products, today announces that President and CEO Thomas A. Nicolette will be stepping down from the board and leaving the Company, effective March 28, 2014. Mr. Nicolette is the principal of Nicolette Consulting Group Limited, a business management consulting firm specializing in capital raising and financial planning. Through a series of consulting agreements, Mr. Nicolette has held the position of ABI's President since February 2007 and Chief Executive Officer since April 2008. Most recently, he played an integral role in ABI's successful listing on the NASDAQ Capital Market raising $15 million to support ABI's growth. Raymond F. Akers, Jr. PhD, the Company's Co-founder and Executive Chairman of the Board will assume the duties of President and CEO effective March 28, 2014; Mr. Nicolette will assist in the transition. Akers Biosciences, Inc. Announces Pricing of Public Offering of Common Stock and Listing on NASDAQ
GlobeNewswire - Thu Jan 23, 12:05PM CST
Akers Biosciences, Inc. (LSE:AKR) (Nasdaq:AKER), (the "Company" or "Akers Biosciences), a leading designer and manufacturer of rapid diagnostic screening and testing products, today announced the pricing of an underwritten public offering of 2,727,000 shares (the "Shares"
of common stock at a public offering price of $5.50 per share. The shares will begin trading on The NASDAQ Capital Market on January 23, 2014 at approximately 2:10 PM EST under the symbol "AKER." The Company expects to receive approximately $15,000,000 in gross proceeds, before underwriting discounts and commissions and offering expenses payable by the Company. The Company has granted the representative of the underwriters a 45-day option to purchase up to 409,050 additional shares of common stock. 
(0)
(0)